Greetings, and welcome to the Streamline Health fourth quarter and fiscal year 2022 earnings conference call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star 0 on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Jacob Goldberger. Thank you, sir. You may begin. Thank you for joining us for the corporate update and financial results review of Streamline Health Solutions for the fourth quarter and fiscal year 2022, which ended January 31, 2023. As the conference call operator indicated, my name is Jacob Goldberger. Joining me on the call today are Tee Green, Chief Executive Officer and Chairman of the Board, Ben Stilwill, President, and Tom Gibson, Chief Financial Officer. At the conclusion of today's prepared remarks, we will open the call for a question-and-answer session. If anyone participating on today's call does not have a full text copy of our press release announcing these results, you can retrieve it from the company's website at www.streamlinehealth.net or from numerous financial websites. Before we begin with prepared remarks, we want to be sure we are clear for everyone on the record how certain information which may be provided today, as with all of our earnings calls, should be viewed. We therefore submit for the record the following statement. Statements made on this conference call that are not historical facts are considered to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These are subject to risks, uncertainties, assumptions, and other factors that could cause actual results to differ materially from those we may discuss. Please refer to the company's press releases and filings made with the U.S. Securities and Exchange Commission, including our most recent Form 10-K annual report, which is on file with the SEC for more information about these risks, uncertainties, and assumptions and other factors. As always, we are presenting management's current analysis of these items as of today. Participants on this call should take into account these risks when evaluating the topics we will discuss. Please note, Streamline Health is not undertaking any commitment or obligation to publicly revise any such forward-looking statements made today. On today's call, we will discuss non-GAAP financial measures such as adjusted EBITDA, booked SaaS ACV, and unaudited figures related to our acquisition of Avelead. Management uses these measures to help provide better insight into our financial performance. Certain items of income and expense are not included in these measures, so these calculations may differ from those which another entity may utilize in calculating their own non-GAAP measures. To help you compare these amounts on consistent terms, please refer to our website at www.streamlinehealth.net and our earnings release for a reconciliation of such non-GAAP measures to the most comparable GAAP measures. I would now like to turn the call over to Tee Green, Chief Executive Officer and Chairman of the Board. Thank you, Jacob, thank you all for joining us this morning. Following my opening remarks, Ben Stilwill, President, will provide an operations and sales update, followed by a financial update from our CFO, Tom Gibson. As a reminder, on August 16th, 2021, we acquired Avelead, and their financial performance will be included in our GAAP results from that day. With that, I'll get started. Beginning with the financial overview. The total contract value of bookings for the 12 months ended January 31st, 2023 totaled $26.5 million, $22.4 million of which was attributable to our SaaS products, an average of $5.6 million of SaaS total contract value per quarter in 2022, exceeding our estimates of $3 million-$5 million of TCV per quarter. Our booking success is a credit to the strong direct sales channel we've built and the value our products provide our clients. Macro headwinds associated with our hospital client staffing and backlog of IT projects continue to hinder conversion of new bookings to revenue. However, during the year, we successfully grew total revenue 43% to $24.9 million, and our SaaS revenues increased $4.2 million of 53% improvement compared to fiscal 2021. During 2022, we began reporting a new metric, booked SaaS ACV, which is the annualized contract value for all agreements that are being recognized into revenue as well as bookings that we have not been implemented. As previously reported, as of January 31st, Booked SaaS ACV was $17.2 million as compared to $10.6 million as of January 31st, 2022, exceeding our previously announced $17 million target. As of January 31st, 2023, we had $6.6 million of cash on our balance sheet, and the balance on our term loan was $9.7 million. We believe our cash on hand is sufficient to achieve positive adjusted EBITDA, less capitalized software development in fiscal 2023. We have access to an additional $2 million of liquidity through our non-formula line of credit. We combined Avelead and eValuator operations on November 1st, 2022. Under Ben's leadership, the integration process has moved more quickly than we expected. Our eValuator and Avelead software solutions share a common selling call point. We have achieved significant cost savings from the integration, $1.5 million of which was executed on November 1, 2022, and was attributable to the elimination of redundant management positions, voluntary reduction of executive salaries and certain other contractors. We anticipate realizing an additional $1.5 million of cost savings throughout fiscal 2023 as compared to our models that had the business operating separately. Looking ahead to fiscal 2023, we expect the continued expansion of Booked SaaS ACV will be a leading indicator of revenue growth to come, and that the business will begin to realize strong incremental margins after achieving a break-even run rate during the second half of the year. Beyond continued growth from new logos and within our existing relationships, we have identified certain key corporate objectives for our existing business in 2023. They are, in no particular order, to have client leveraging both our flagship solutions, RevID and eValuator, an Epic-based facility utilizing RevID, improved performance from our partner channel, and achieving a break-even adjusted EBITDA less capitalized software. Please note, as our SaaS revenues and Booked SaaS ACV continue to expand, we no longer believe that each individual contract signature is material news. Going forward, we will no longer press release individual bookings unless we deem them significant. We remain committed to keeping you apprised of our progress against our key corporate objectives and of significant contract signings. We remain confident in our growth prospects going forward. Our products and services are part of the answer for our hospital clients and the macroeconomic burdens they are facing today. Unfortunately for our industry, that demand is not enough to guarantee success. Our clients are experiencing a continued hangover effect from the impacts of the COVID pandemic on their hospital operations, which has manifested in a backlog of potential high-priority projects. Our team is working hard to ensure they are clearly communicating the impact of our automated pre-bill solutions, which enable our clients to capture and bill accurately for all the care they have provided. This has never been more critical to our industry than it is today, and we believe our bookings will continue to accelerate as a result. We maintain our stated goal to exit fiscal 2023 with $30 million of booked SaaS ACV. With that, I'd like to turn the call over to our President, Mr. Ben Stilwill. Thank you, T. As T alluded to, the integration of Avelead and eValuator has proceeded smoothly, and I'm grateful to our team members who have quickly adapted to their rapidly changing teams, all while maintaining a high level of service and commitment to client success. Internally, the team at Streamline Health is working toward five annual priorities, which will support the corporate objectives T laid out and fuel our long-term growth. The first is scaling the RevID and Compare technology for growth. Second, increasing our client effectiveness through eValuator usability improvements. The third is enhancing the service delivery of RevID and Compare products. The fourth being doubling eValuator client outcomes through enhanced rules, and five, expanding our reach to new logo clients. Our client conversations remain focused on their increased denial rates and the need for automation within the revenue cycle. We recently published a case study of eValuator's impact for one of our clients, Cooper University Health Care, a 660 bed hospital system which employs 961 individual physician providers. Cooper found $3.2 million of financial impact as a result of their use of eValuator, which translated to a 16 times ROI. The case study also confirmed Cooper's reasons for selecting eValuator. In addition to the financial impact, the Cooper team highlighted the tool's ease of use and our robust reporting suite. Their team was able to leverage eValuator's results and insights to improve the organization and justify the addition of FTEs to optimize future outcomes. Said differently, the organization found that staff empowered by our automated solutions became a net positive for the organization rather than a cost center. I believe being able to share results like these will provide additional momentum as we work toward the sales-related goals we highlighted earlier. Within innovation, our primary focus remains on improvements to the back-end architecture of our RevID and Compare suite. We are making improvements to those products that will reduce the effort associated with our implementations and improve the user experience. Easing the burden associated with the implementation of RevID enables us to recognize revenue and generate customer ROI earlier. We also continue to make incremental improvements to the eValuator system as well, expanding our rule set and overall making the solution more effective. We are taking some initial steps to incorporate machine learning techniques into how our rules are generated and maintained for eValuator, which should help us develop more effective rules and translate to a higher ROI for our clients. The client-centric service organization we developed within eValuator has been a true differentiator for us in the market. As I highlighted above, prospective clients are actively searching for solutions that are well supported. We're maintaining our cadence of monthly education and quarterly executive client meetings to establish the value of the tools we're providing. Administrative staff within hospitals remain strained and understaffed, especially within their IT departments. This has delayed implementation timing for our solutions, and our implementation teams are working hard to ensure that we are never the bottleneck. On the sales front, we were thrilled to report TCV SaaS bookings of $22.4 million for fiscal 2022, above our expected average of $3 million-$5 million for TCV SaaS bookings per quarter. The achievement of significant bookings growth in fiscal 2022 was the result of the growth team structure, which Amy Seberras, our Chief Growth Officer, established early in the year. The shifts in our marketing efforts are palpable, and our branding refresh was received well by our clients. Finally, we have spoken in the past about the lead time from contract signature to revenue or the implementation window that has been hindered by competing projects at our hospital clients. For eValuator, this has been steadily improving. We experienced two new go-lives in Q4 of 2022. We have four go-lives in Q1 of 2023 and have two more slated for early in Q2 2023. These new implementations will have a meaningful impact on recognized SaaS revenue year-over-year and on a sequential quarterly basis in fiscal 2023. Before I turn the call over to Tom, I would like to thank all of our hardworking associates who are supporting our mission to ensure our healthcare provider clients are paid for all the care that they provide. I'm very excited to lead our talented team and believe strongly that our innovation plus service equals growth formula will yield tremendous results for all of us as we continue to execute and expand. With that, I'll hand the call over to our CFO, Tom Gibson. Thank you, Ben. As team mentioned in his opening remarks, we acquired Avelead on August 16, 2021. All operations of Avelead are included in our reported GAAP numbers from that date. We also provide pro forma numbers that assume we owned Avelead from the beginning of the prior year period. For the year ended January 31, 2023, total GAAP revenue increased 43% to $24.9 million. For the year ended January 31, 2023, SaaS revenue grew 53% compared to fiscal 2021. $3.4 million of the increase in SaaS revenue was attributable to the acquisition of Avelead. Total revenue for fiscal year 2022 and 2021 was $24.9 million of actual and $22.6 million on a pro forma basis. We have been impacted by headwinds that face our hospital clients. Hospitals are overcoming shrinking operating margins, personnel shortages, and significant backlog of IT projects, a hangover effect from COVID. These headwinds impact our contracting process and our contract implementation timeline. We do not know how long these delays will impact our clients and accordingly, our recognized revenue. $5.4 million of our annualized SaaS contract value is unimplemented as of January 31, 2023. As these contracts are implemented in the coming quarters, our investors will see strong SaaS revenue growth. Total operating expense was $35.7 million and $28.1 million for fiscal year 2022 and 2021 respectively. There is $4.3 million and $3.7 million in fiscal year 2022 and 2021 respectively of depreciation and amortization in those operating expense totals. $12.2 million of the increase is attributable to the acquisition of Avelead. The company experienced higher severance, bonus, and travel and entertainment expenses than that of the previous year. Fiscal 2022 net loss totaled $11.4 million compared to a loss of $6.9 million in fiscal 2021. The higher net loss in fiscal 2022 is the result of a full year of Avelead operations as compared with a partial year in fiscal 2021. Net loss in the fourth quarter of fiscal 2021 included each of $2.3 million of income related to a loan forgiveness and $1.9 million of income from Avelead acquisition earn out valuation adjustment. Fiscal 2022 adjusted EBITDA was a loss of $3.8 million compared to an adjusted EBITDA loss of $2 million in fiscal 2021. The higher EBITDA loss can be explained by a full year of Avelead operations in fiscal 2022 as compared with a partial year in fiscal year 2021. Investments in the architecture of the Avelead technology, higher headcount and salaries for our upgraded sales function and administrative costs such as performance bonuses and travel and entertainment in fiscal 2022 as compared with fiscal 2021. Certain of these costs have been curtailed due to the integration of Avelead and eValuator units. Moving to the balance sheet. As of January 31, 2023, we had $6.6 million of cash on hand compared to $9.9 million at January 31, 2022. The company completed a registered direct offering in the fourth quarter of fiscal 2022, which resulted in gross proceeds of approximately $8.3 million. Under the Avelead acquisition agreement, the company is contracted to provide additional consideration on each of the first two 12-monthly anniversaries of the closing date. The first of these payments were paid in the fourth quarter of fiscal 2022. The payment was made using approximately $2 million of cash and $3 million of restricted common stock. The second payment will also be paid in cash and stock and is valued on the balance sheet at approximately $3.7 million. Of this amount, it is estimated that we will pay $1.5 million in cash. The liability is referred to as acquisition earn-out liability on the company's balance sheet. Subsequent to the closing of the Avelead acquisition in 2021, we entered into a five-year, $10 million term loan with Bridge Bank. There was no repayment of the term loan required in the first year following the close. $500,000 or $41,667 monthly is required in the second year following the close. The balance of our term loan as of January 31, 2023 was $9.7 million. As T mentioned, we recently expanded our relationship with Bridge Bank to include a $2 million line of credit which we can draw on if necessary. We believe that our cash on hand is sufficient to achieve a positive adjusted EBITDA less capitalized software development, but we are pleased to have this access to additional liquidity. As T mentioned, we have introduced a new metric that provides an annualized contract value for client agreements that are being recognized into revenue, as well as an annualized co-contract value for client agreements that have not implemented. We refer to this figure as our booked SaaS ACV, where ACV stands for annual contract value. We believe booked SaaS ACV will provide a proxy for our annual recognized revenue as if all executed contracts are live and recognizing revenue. Please note that the recognition of revenue from our signed contracts is subject to the timing of implementations. Implementations may sometimes be delayed by clients due to competing projects or be timed after a larger implementation of another system. Our booked SaaS ACV as of January 31, 2023 totaled $17.2 million, and $5.4 million of that booked SaaS ACV was not implemented. Subsequent to the end of fiscal 2022, as of March 31, 2023, our booked SaaS ACV totaled $17.6 million, $5.3 million of which was unimplemented. We remain focused on continued growth of SaaS revenue. On its current co-cost structure, we believe our overall business will achieve breakeven at a SaaS revenue run rate of $17 million. We achieved this level of bookings in Q4 of 2022 and expect to have this revenue fully implemented during the second half of fiscal 2023. The company is realizing incremental SaaS gross margins above 80%. I am proud of the progress we have made in fiscal 2022. I would like to commend our staff on their recent success. That concludes my review. I'll now turn the call back to Tee Green for his closing remarks. T? Thank you, Tom. We continue to enable healthcare providers to proactively address revenue leakage and improve financial performance and have taken major steps forward to drive recurring revenue streams that better position our company for growth and to deliver significant shareholder value over the long term. The alignment has enabled us near-term visibility to cash flow without losing momentum in growth or innovation. Before we begin our Q&A session, I'd like to thank the entire Streamline team once again for the hard work and dedication. Their contributions are essential for us to support our healthcare providing clients and ensure they have the necessary tools to free up time and resources to provide quality care for the communities they serve. Thank you all for your support of Streamline Health and our vision. I'd like to open the call up to your questions. Operator? Thank you. We will now be conducting a question and answer session. If you would like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate that your line is in the question queue. You may press star two if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. One moment please while we poll for questions. Our first question comes from Matt Hewitt with Craig-Hallum Capital Group. Please proceed with your question. Good morning, gentlemen. Congratulations on the strong finish to 2023. Maybe first up, I was hoping we could dig in a little bit more on the selling environment. You talked about some of the headwinds that you experienced last year, the hangover from COVID. Some of the commentary coming out of public hospitals, HCA, Tenet, for example, appears to show some improvement, particularly on the staffing side. The procedure volumes are following suit. How should we be thinking about that in context of what you're seeing, you know, do you expect for those headwinds to maybe abate a little bit as the year progresses? How quickly do you think that that will translate into improvements in not only the contracting but also the implementations? Yeah. Matt, Tee here. Thanks for the question and the comments. It was a great year, and we're excited about 2023 and 2024. You're right, you pointed out, like Tenet, for example, right, incredible growth, revenue exceeding projections in their reports, profitability exceeding. On the other side of the camp, you have hospitals going bankrupt. It's the tale of two cities, right, in the healthcare system. I do think. Well, I know right now we're still in the headwinds. We still have, you know, a lot of health systems that are still dealing with the post-COVID stuff, and they're getting through their contracts. Their IT staffs are still stretched, so the implementation still can be delayed. You know, they're dealing with a financial environment that's a little different now, you know, with these health systems and interest rates and what they're having to go through. All of that, though, points to more and more, I guess, tailwinds for why they need Streamline. You know, these are all, these are all good things, but they are. I do think the first half of this year is still gonna be like the back half of last year. It's gonna be, fighting for time in the CFO's office, fighting for time in the general counsel's office, and then fighting for time, in the head of the IT department. That, that's just something we have to be better than others. One, I think we have an incredible growth team, led by Amy. Second, our technology is exactly what they need. It can be implemented quickly, it requires very little of their IT staff, and it solves, obviously major issues such as revenue, but also staffing. Ben, you wanna opine any further on that? Yeah. I think you hit it on the head. Our current clients and pipeline prospective clients are definitely feeling the need for automation and just finding dollars where they can. Volumes and margins have improved as we've kind of seen, but they're still struggling to make sure that there's continued improvement. That's really helpful. Thank you. Maybe just to follow up on that as far as the pipeline is concerned, you know, are you seeing that continue to expand? Are, you know, are things moving, albeit maybe slower than you would hope, but maybe moving through that pipeline where you're still feeling confident about the $30 million in booked SaaS ACV exiting this year? You know, the pipeline continues to expand in quantity, but I would say more in quality. We've gone through significant analysis of historical deals and trying to really determine what the ideal client profile is for Streamline, especially on the eValuator side. Matt, not only is our pipeline growing, but the pipeline's growing of where we believe we can be the most impactful, meaning who's most likely to lean into the eValuator solutions? Where can we generate the largest ROI for the client? You know, so those are some of the things. I wish I could show you some of the details, but it's more exciting than ever about the pipeline because of the quality of the pipeline, if that makes sense. Absolutely. Yep. Thank you. Then maybe one last one for me, and I'll hop back in the queue. As far as gross margins are concerned, a nice uptick here, in the fourth quarter. I think you mentioned that the SaaS, margins, are 80%+ on the incremental, you know, implementations. How should we be thinking about that line on total gross margins for the company as you progress through 2023 and maybe as you look out a few years? I'll let Tom get the details, they spanned. Thank you, T, and hey, Matt. Yeah. There's about almost 20% of that SaaS cost of goods line is related to capitalized software development amortization. We had about, on a normalized kinda cash basis, around 65%-70% on a cash basis going through that as a gross margin. You're gonna see that continue to expand with volume. Got it. All right. Thank you very much, and congratulations again on the strong finish. You betcha. Our next question comes from Brooks O'Neil with Lake Street Capital Markets. Please proceed with your question. Good morning, everyone. I just want to be sure I understand sort of what you're talking about with the non-implemented business. I think you said $5.4 million of the booked ACV has not been implemented. I assume that's not in the revenue line yet. T., if you don't mind me answering. Hey, Brooks, how are you doing? Good, Tom. That is 100% correct. Okay. You may have heard in Ben's remarks that we had four go-lives in Q1 and two that are coming up in early Q2. You're gonna see that revenue start being recognized into revenue on those eValuator deals in 2023. That's why we talk about the strong growth on that revenue line. Yeah, that's great. Now, with the headwinds still out there, though, as we book new contracts, I'm assuming there's going to be some implementation delays on those as well. So there's going to be sort of this continuous process of putting more contracts in the bucket, implementing past contracts, but not necessarily catching up in terms of a shorter time between contract signing and implementation and revenue recognition. Is that the right way to think about it? T., you want me to start off and then you can- Yeah, go ahead. Go ahead, I'll just follow up. Yeah. Thank you. Brooks, what I am seeing is that delay getting a lot shorter, especially with eValuator. Is it good? Yeah. With RevID, it's a client-by-client thing, and it depends. Mm-hmm -heavily on whether we're following Cerner or not. I would tell you're seeing on the eValuator side that getting a lot shorter. With RevID, we plan on making it shorter, but it's not there yet as far as, the timing. T.? No. That's it. No, nothing further. Okay, that's great. Let me just ask one more. If I was listening carefully, and I try to, it sounded to me like there might be a subtle shift in kind of the positioning you guys are coming to market with in terms of, I always thought in the past the focus was on pre-bill because that was going to enable these hospital systems to, you know, avoid the disallowed revenue and whatnot. I think I was hearing you say today that automation of the revenue cycle may be resonating better with the hospitals. Am I picking that up properly, or am I overreading into your comments? might be overreading just a bit, Brooks. We are- Okay absolutely focused on pre-bill operations. We are the leader in pre-bill operations. In fact, we're beginning to maybe ask questions, who's the vice president of pre-bill for the health system? I say that. Yeah a bit jokingly. Sure. That position doesn't exist right now in the health systems, but it should. We are the leader in this side of the industry. No. You maybe read a little further into it, but it all evolves around automation as well, but on the pre-bill side. Yeah. Okay, I get that. Let me just ask one last thing. Tom mentioned the following Cerner. Help me to understand what's going on with Cerner, obviously with the integration with Oracle. Is that ultimately gonna be a positive for you, or is that just that integration on their side, something that slows you guys down for a period of time until they kinda get through? Well, it's, you know, the Oracle's. A lot of that, I just, we don't have insight into Oracle's strategy, right? Oracle's Cerner. Yes you know, that's something that we really don't influence at all. When you look at Oracle's, you know, Cerner and you look at the Cerner healthcare, you know, strategy as it relates to pre-bill initiatives, that hasn't changed. In fact, I would say they've gotten more excited coming out of QBR with the team about what eValuator can do and, you know, RevID's already been part of the Cerner plan, eValuator has not. You know, I don't. The pre-bill side of the Cerner strategy is accelerating, and that's good for us. Great. Thank you very much for taking my questions. Thank you. There are no further questions at this time. I would now like to turn the floor back over to Jacob Goldberger for closing comments. Thank you all again for your interest and support of Streamline Health. If you have any additional questions or need more information, please contact me at jacob.goldberger@streamlinehealth.net. We look forward to speaking with you again when we discuss our first quarter and 2020 financial performance. Thank you. This concludes today's conference. You may disconnect your lines at this time. Thank you for your participation.